Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30357022 | 1.00 | ABCG2 (0.31) | ABCG2 | |
| Hydrochloric Acid SCHEMBL28432599 | 0.98 | ABCG2 (0.30) | ABCG2 | |
| SCHEMBL29937535 | 0.85 | CDC25B (0.40) | — | |
| SCHEMBL4528417 | 0.75 | CDC25B (0.33) | ABCG2 | |
| SCHEMBL29470864 | 0.72 | CDC25B (0.34) | — | |
| SCHEMBL7927617 | 0.72 | CDC25B (0.34) | — | |
| SCHEMBL10354666 | 0.69 | ABCG2 (0.39) | ABCG2 | |
| SCHEMBL5886591 | 0.69 | ABCG2 (0.39) | ABCG2 | |
| SCHEMBL1899000 | 0.67 | ABCG2 (0.31) | ABCG2 | |
| SCHEMBL29372537 | 0.67 | ABCG2 (0.31) | ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586266-A | Indenopyrazoles compounds with anticancer activity and synthesis method thereof | 河南师范大学 | 2024-02-23 | — | — | CN | claimed |
| CN-115838371-A | Synthetic method of indenopyrazole compound | 河南师范大学 | 2023-03-24 | — | — | CN | claimed |
| CN-111393368-B | Indenopyrazole hydrochloride derivative and preparation method and application thereof | 山东大学 | 2021-06-18 | — | — | CN | claimed |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2020-12-15 | — | — | US | claimed |
| CN-111393368-A | Indenopyrazole hydrochloride derivative and preparation method and application thereof | 山东大学 | 2020-07-10 | — | — | CN | claimed |
| US-10059674-B2 | Design, synthesis, and biological evaluation of 1-methyl-1, 4-dihyrdoindeno[1,2-C]pyrazole analogues as potential anticaner agents targeting tubulin colchicine binding site | ACT PHARMA CO., LTD. (CN) | 2018-08-28 | — | — | US | claimed |
| US-9974795-B2 | Anticancer agent composition | CARNA BIOSCIENCES, INC. (JP) | 2018-05-22 | — | — | US | claimed |
| US-20170327468-A1 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF 1-METHYL-1, 4-DIHYRDOINDENO[1,2-C]PYRAZOLE ANALOGUES AS POTENTIAL ANTICANER AGENTS TARGETING TUBULIN COLCHICINE BINDING SITE | JOYOCHEM CO., LTD (CN) | 2017-11-16 | — | — | US | claimed |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CARNA BIOSCIENCES, INC. (JP) | 2017-03-09 | — | — | US | claimed |
| EP-3100742-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences Inc. (JP) | 2016-12-07 | — | — | EP | claimed |
| EP-1696928-A1 | CDK2 ANTAGONISTS AS SHORT FORM C-MAF TRANSCRIPTION FACTOR ANTAGONISTS FOR TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2006-09-06 | — | — | EP | claimed |
| US-20050159432-A1 | Short form c-Maf transcription factor antagonists for treatment of glaucoma | ALCON, INC. (CH) | 2005-07-21 | — | — | US | claimed |
| WO-2005063252-A1 | CDK2 ANTAGONISTS AS SHORT FORM C-MAF TRANSCRIPTION FACTOR ANTAGONISTS FOR TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2005-07-14 | — | — | WO | claimed |
| US-6130228-A | Polycyclic compounds | UNIVERSITY OF STRATHCLYDE (GB) | 2000-10-10 | — | — | US | claimed |
| EP-0877735-A1 | POLYCYCLIC COMPOUNDS | University of Strathclyde (GB) | 1998-11-18 | — | — | EP | claimed |
| WO-1997019929-A1 | POLYCYCLIC COMPOUNDS | THE UNIVERSITY OF STRATHCLYDE (GB) | 1997-06-05 | — | — | WO | claimed |
| US-20250074989-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE | METANOIA BIO INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20240269111-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | disclosed |
| EP-0680471-A1 | 5-SUBSTITUTED 4-METHYL-5H-INDENO 1,2-b]PYRIDINES, THEIR PREPARATION AND USE AS HERBICIDES AND PLANT GROWTH REGULATORS | BASF AKTIENGESELLSCHAFT (DE) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017044-A1 | 5-SUBSTITUTED 4-METHYL-5H-INDENO[1,2-b]PYRIDINES AND 9-SUBSTITUTED 1-METHYL-IH-INDENO[2,1-c]PYRIDINES, THEIR PREPARATION AND USE AS HERBICIDES AND PLANT GROWTH REGULATORS | BASF AKTIENGESELLSCHAFT (DE) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059674-B2 | Design, synthesis, and biological evaluation of 1-methyl-1, 4-dihyrdoindeno[1,2-C]pyrazole analogues as potential anticaner agents targeting tubulin colchicine binding site | TUBA1C, TUBB1, TUBB3 | ABCG2 47/4885 |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CDC7, CDC16, MCM7 | ABCG2 2306/4885 |
| US-20170327468-A1 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF 1-METHYL-1, 4-DIHYRDOINDENO[1,2-C]PYRAZOLE ANALOGUES AS POTENTIAL ANTICANER AGENTS TARGETING TUBULIN COLCHICINE BINDING SITE | TUBA1C, TUBB1, TUBB3 | ABCG2 47/4885 |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | ABCG2 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.